Yan Yi, Liu Longfei, Zhou Jingyu, Li Liling, Li Yuan, Chen Minfeng, Wang Long, He Wei, Guan Xiao, Zu Xiongbing, Qi Lin
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
J Cancer Res Clin Oncol. 2015 Feb;141(2):345-52. doi: 10.1007/s00432-014-1740-1. Epub 2014 Sep 2.
We seek to summarize the clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinoma (SRCC), an uncommon type of renal cell carcinoma.
Between 2004 and 2012, 23 patients with SRCC were treated at a large urology center in south central China. We collect patient's clinicopathologic features from medical records to assess diagnosis, prognostic factors and efficacy of systemic therapy. Clinical data were absent in 3 cases, and 20 patients were enrolled in the final study.
Immunohistochemically, almost all SRCC expressed cytokeratin (91%), epithelial membrane antigen (87%) and vimentin (100%). Sarcomatoid differentiation occurs in various kinds of subtypes of RCC with almost the same probability. The median tumor size was 10.5 cm. The CT findings of these tumors revealed low-density (n = 5; 25%) or mixed (n = 15; 75%) masses with necrotic areas and often showed an infiltrative morphology (n = 15; 75%). All 20 cases demonstrated heterogeneous enhancement, and eleven (55%) cases demonstrated >50% necrosis. Six cases complicated with calculus and hydronephrosis. Sixteen (80%) patients demonstrated invasions of tissues localized in Gerota's fascia, and 8 (40%) tumors invaded beyond Gerota's fascia. Fifteen (75%) patients demonstrated lymph node metastasis, and sixteen (80%) patients had distant metastasis. Five patients received systemic therapy, and one patient given high-dose interferon-α had a completely response, and one patient received chemotherapy based on gemcitabine had partial response. The median overall survival of all patients was 5.8 months. Patients without distant metastasis had a median overall survival of 35 months compared with 3 months of those with distant metastasis (P < 0.002). The percentage of the sarcomatoid components did not have an obvious influence to the prognosis (P = 0.197).
Heterogeneity, hugeness, infiltration and necrosis are typical image features of SRCC. The prognosis of SRCC is poor and clinic stage especially the existence of distant disease is the important factor influencing prognosis.
我们旨在总结肾肉瘤样癌(SRCC)这一罕见类型肾细胞癌的临床病理特征及预后因素。
2004年至2012年间,中国中南部一家大型泌尿外科中心收治了23例SRCC患者。我们从病历中收集患者的临床病理特征,以评估诊断、预后因素及全身治疗的疗效。3例患者临床资料缺失,最终纳入研究的患者为20例。
免疫组化显示,几乎所有SRCC均表达细胞角蛋白(91%)、上皮膜抗原(87%)和波形蛋白(100%)。肉瘤样分化在各种类型的肾细胞癌亚型中出现的概率几乎相同。肿瘤中位大小为10.5 cm。这些肿瘤的CT表现为低密度肿块(n = 5;25%)或混合密度肿块(n = 15;75%),伴有坏死区域,且常表现为浸润性形态(n = 15;75%)。所有20例均表现为不均匀强化,11例(55%)坏死率>50%。6例合并结石和肾积水。16例(80%)患者表现为肿瘤侵犯肾周筋膜内组织,8例(40%)肿瘤侵犯超出肾周筋膜。15例(75%)患者出现淋巴结转移,16例(80%)患者发生远处转移。5例患者接受了全身治疗,1例给予大剂量干扰素-α治疗获得完全缓解,1例接受吉西他滨化疗获得部分缓解。所有患者的中位总生存期为5.8个月。无远处转移患者的中位总生存期为35个月,而有远处转移患者为3个月(P < 0.002)。肉瘤样成分所占比例对预后无明显影响(P = 0.197)。
异质性、巨大、浸润和坏死是SRCC的典型影像特征。SRCC预后较差,临床分期尤其是远处转移的存在是影响预后的重要因素。